Additionally, a study using an oral CCR4 antagonist combined with ICB (anti-CTLA-4 or anti-PD-1) therapy in a mouse tumor model demonstrated that the combination therapy is more effective against tumors than monotherapy (170, 171). This evidence concerns the gene CCR4 and neoplasm.